Although the Australian tobacco market is considered to be mature, heavily regulated, and per capita consumption is in decline (see Chapter 2), tobacco companies remain highly profitable entities and continue to successfully operate within Australia
The inhalation of toxic substances in tobacco smoke, such as carbon monoxide and arsenic, poses severe health risks not only to smokers but also to non-smokers exposed to second-hand smoke
In 2018 FDA Tobacco Product Scientific Advisory Committee found that the IQOS did not substantially reduce risks of tobacco-related death and disease, and in 2019, FDA did not approve the products for a risk modification label
Ji M, Zhang Y, Li N, Wang C, Xia R, Zhang Z et al (2017) Nicotine component of cigarette smoke extract (CSE) decreases the cytotoxicity of CSE in BEAS-2B cells stably expressing human cytochrome P450 2A13
Two levels of difficulty are included